Jim Simons
GMAB icon

Jim Simons’s Genmab GMAB Stock Holding History

Jim Simons’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$96.6M Sell
3,517,850
-896,700
-20% -$23.8M 0.13% 162
2026
Q1 		$118M Buy
4,414,550
+921,700
+26% +$27.6M 0.19% 118
2025
Q4 		$108M Buy
3,492,850
+671,307
+24% +$20.9M 0.17% 136
2025
Q3 		$86.5M Buy
2,821,543
+54,793
+2% +$1.34M 0.11% 194
2025
Q2 		$57.2M Buy
2,766,750
+504,400
+22% +$10.4M 0.08% 294
2025
Q1 		$44.3M Buy
2,262,350
+336,200
+17% +$7.05M 0.07% 360
2024
Q4 		$40.2M Buy
1,926,150
+139,722
+8% +$3.07M 0.06% 393
2024
Q3 		$43.6M Buy
1,786,428
+323,969
+22% +$8.66M 0.07% 369
2024
Q2 		$36.8M Buy
1,462,459
+103,859
+8% +$2.94M 0.06% 380
2024
Q1 		$40.6M Sell
1,358,600
-136,200
-9% -$4M 0.06% 367
2023
Q4 		$47.6M Buy
1,494,800
+320,800
+27% +$10.1M 0.07% 310
2023
Q3 		$41.4M Buy
1,174,000
+334,900
+40% +$12.8M 0.07% 316
2023
Q2 		$31.9M Sell
839,100
-210,500
-20% -$8.39M 0.05% 457
2023
Q1 		$39.6M Sell
1,049,600
-141,100
-12% -$5.42M 0.05% 414
2022
Q4 		$50.5M Buy
1,190,700
+274,300
+30% +$11.3M 0.07% 333
2022
Q3 		$29.4M Sell
916,400
-63,800
-7% -$2.24M 0.04% 498
2022
Q2 		$31.8M Sell
980,200
-108,300
-10% -$3.51M 0.04% 511
2022
Q1 		$39.4M Buy
1,088,500
+14,100
+1% +$484K 0.05% 428
2021
Q4 		$42.5M Buy
1,074,400
+175,600
+20% +$7.32M 0.05% 380
2021
Q3 		$39.3M Buy
898,800
+13,900
+2% +$624K 0.05% 389
2021
Q2 		$36.1M Sell
884,900
-107,400
-11% -$4.14M 0.05% 448
2021
Q1 		$32.6M Sell
992,300
-318,900
-24% -$12M 0.04% 529
2020
Q4 		$53.3M Sell
1,311,200
-352,000
-21% -$13.2M 0.06% 325
2020
Q3 		$60.9M Buy
1,663,200
+560,103
+51% +$20.3M 0.06% 331
2020
Q2 		$37.4M Buy
1,103,097
+954,697
+643% +$26M 0.03% 520
2020
Q1 		$3.14M Buy
+148,400
New +$3.31M ﹤0.01% 1824

Other funds holding GMAB

Paradigm Biocapital Advisors
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Orbis Allan Gray
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Deerfield Management
Deerfield Management New York $9.6B AUM 113.36% 1-Year Est. Return
Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sofinnova Investments
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Harding Loevner
Harding Loevner Bridgewater, New Jersey $10.6B AUM 19.39% 1-Year Est. Return

Jim Simons's GMAB Position: Q2 2026 in Review

Jim Simons reduced its Genmab (GMAB) stake by 20% in Q2 2026, selling an estimated $23.8M and leaving 3,517,850 shares worth $96.6M. The position accounts for 0.13% of the portfolio, ranked #162.

Jim Simons first reported a position in GMAB in Q1 2020 and has held it in 26 quarters since. The position peaked at $118M in Q1 2026. 292 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Jim Simons held 3,517,850 shares of Genmab worth $96.6M as of Q2 2026.
  • Jim Simons sold 896,700 Genmab shares in Q2 2026, an estimated $23.8M.
  • Genmab made up 0.13% of Jim Simons's portfolio in Q2 2026, its #162 holding.
  • Jim Simons first reported a position in Genmab in Q1 2020 and has held it in 26 quarters since.
  • Jim Simons's Genmab position peaked at $118M in Q1 2026.
  • 292 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.